Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/2101
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorFREGNANI, Jose Humberto Tavares Guerreiro-
dc.contributor.authorCARVALHO, Andre Lopes-
dc.contributor.authorELUF-NETO, Jose-
dc.contributor.authorRIBEIRO, Karina de Cassia Braga-
dc.contributor.authorKUIL, Larissa de Melo-
dc.contributor.authorSILVA, Tauana Arcadepani da-
dc.contributor.authorRODRIGUES, Silvia Lapola-
dc.contributor.authorMAUAD, Edmundo Carvalho-
dc.contributor.authorLONGATTO-FILHO, Adhemar-
dc.contributor.authorVILLA, Luisa Lina-
dc.date.accessioned2013-09-23T16:43:46Z-
dc.date.available2013-09-23T16:43:46Z-
dc.date.issued2013-
dc.identifier.citationPLOS ONE, v.8, n.4, article ID e62647, 9p, 2013-
dc.identifier.issn1932-6203-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/2101-
dc.description.abstractIntroduction: The implementation of a public HPV vaccination program in several developing countries, especially in Latin America, is a great challenge for health care specialists. Aim: To evaluate the uptake and the three-dose completion rates of a school-based HPV vaccination program in Barretos (Brazil). Methods: The study included girls who were enrolled in public and private schools and who regularly attended the sixth and seventh grades of elementary school (mean age: 11.9 years). A meeting with the parents or guardians occurred approximately one week before the vaccination in order to explain the project and clarify the doubts. The quadrivalent vaccine was administered using the same schedule as in the product package (0-2-6 months). The school visits for regular vaccination occurred on previously scheduled dates. The vaccine was also made available at Barretos Cancer Hospital for the girls who could not be vaccinated on the day when the team visited the school. Results: Among the potential candidates for vaccination (n = 1,574), the parents or guardians of 1,513 girls (96.1%) responded to the invitation to participate in the study. A total of 1,389 parents or guardians agreed to participate in the program (acceptance rate = 91.8%). The main reason for refusing to participate in the vaccination program was fear of adverse events. The vaccine uptake rates for the first, second, and third doses were 87.5%, 86.3% and 85.0%, respectively. The three-dose completion rate was 97.2%. Conclusions: This demonstrative study achieved high rates of vaccination uptake and completion of three vaccine doses in children 10-16 years old from Brazil. The feasibility and success of an HPV vaccination program for adolescents in a developing country may depend on the integration between the public health and schooling systems.-
dc.description.sponsorshipCNPq [573799/2008-3]-
dc.description.sponsorshipFAPESP [2008/57889-1]-
dc.description.sponsorshipMISP (Merck Investigator Studies Program)-
dc.description.sponsorshipMerck Co., Inc.-
dc.language.isoeng-
dc.publisherPUBLIC LIBRARY SCIENCE-
dc.relation.ispartofPlos One-
dc.rightsopenAccess-
dc.subject.otherhpv vaccination-
dc.subject.otherquadrivalent vaccine-
dc.subject.otherdelivery strategies-
dc.subject.otherparticle vaccine-
dc.subject.otherincome countries-
dc.subject.otherunited-states-
dc.subject.othercoverage-
dc.subject.otheraustralia-
dc.subject.otherefficacy-
dc.subject.othertrial-
dc.titleA School-Based Human Papillomavirus Vaccination Program in Barretos, Brazil: Final Results of a Demonstrative Study-
dc.typearticle-
dc.rights.holderCopyright PUBLIC LIBRARY SCIENCE-
dc.identifier.doi10.1371/journal.pone.0062647-
dc.identifier.pmid23638130-
dc.subject.wosMultidisciplinary Sciences-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalFREGNANI, Jose Humberto Tavares Guerreiro:Barretos Canc Hosp IEP HCB, Res & Teaching Inst, Barretos, Brazil; Santa Casa Sao Paulo Med Sch FCMSCSP, Natl Inst Sci & Technol Dis Associated Papillomav, Sao Paulo, Brazil-
hcfmusp.author.externalCARVALHO, Andre Lopes:Barretos Canc Hosp IEP HCB, Res & Teaching Inst, Barretos, Brazil-
hcfmusp.author.externalRIBEIRO, Karina de Cassia Braga:Santa Casa Sao Paulo Med Sch FCMSCSP, Natl Inst Sci & Technol Dis Associated Papillomav, Sao Paulo, Brazil; Santa Casa Sao Paulo Med Sch FCMSCSP, Dept Social Med, Sao Paulo, Brazil-
hcfmusp.author.externalKUIL, Larissa de Melo:Barretos Canc Hosp IEP HCB, Res & Teaching Inst, Barretos, Brazil-
hcfmusp.author.externalSILVA, Tauana Arcadepani da:Barretos Canc Hosp IEP HCB, Res & Teaching Inst, Barretos, Brazil-
hcfmusp.author.externalRODRIGUES, Silvia Lapola:Barretos Canc Hosp IEP HCB, Res & Teaching Inst, Barretos, Brazil-
hcfmusp.author.externalMAUAD, Edmundo Carvalho:Barretos Canc Hosp IEP HCB, Res & Teaching Inst, Barretos, Brazil-
hcfmusp.author.externalVILLA, Luisa Lina:Santa Casa Sao Paulo Med Sch FCMSCSP, Natl Inst Sci & Technol Dis Associated Papillomav, Sao Paulo, Brazil-
hcfmusp.description.articlenumbere62647-
hcfmusp.description.issue4-
hcfmusp.description.volume8-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-84876533181-
hcfmusp.origem.idWOS:000318340400119-
hcfmusp.publisher.citySAN FRANCISCO-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceArrossi S, 2012, VACCINE, V30, P2467, DOI 10.1016/j.vaccine.2012.01.032-
hcfmusp.relation.referenceBrasil, 2010, CENS 2010-
hcfmusp.relation.referenceBrazil, 2011, SI PNI SIST INF PROG-
hcfmusp.relation.referenceBrotherton JML, 2011, LANCET, V377, P2085, DOI 10.1016/S0140-6736(11)60551-5-
hcfmusp.relation.referenceBurchell AN, 2006, VACCINE, V24, P52, DOI 10.1016/j.vaccine.2006.05.031-
hcfmusp.relation.referenceDorell Christina, 2012, Morbidity and Mortality Weekly Report, V61, P671-
hcfmusp.relation.referenceChadenier GMC, 2011, VACCINE, V29, P4405, DOI 10.1016/j.vaccine.2011.04.007-
hcfmusp.relation.referenceFagot JP, 2011, VACCINE, V29, P3610, DOI 10.1016/j.vaccine.2011.02.064-
hcfmusp.relation.referenceFairley CK, 2009, SEX TRANSM INFECT, V85, P499, DOI 10.1136/sti.2009.037788-
hcfmusp.relation.referenceFerlay J, 2011, IARC CANCERBASE-
hcfmusp.relation.referenceFerlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516-
hcfmusp.relation.referenceGarland SM, 2011, PREV MED, V53, pS29, DOI 10.1016/j.ypmed.2011.08.015-
hcfmusp.relation.referenceGarland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760-
hcfmusp.relation.referenceGoldie SJ, 2007, VACCINE, V25, P6257, DOI 10.1016/j.vaccine.2007.05.058-
hcfmusp.relation.referenceImmunise Australia Program. Human Papillomavirus (HPV), 2011, HUM PAP HPV INF NAT-
hcfmusp.relation.referenceLadner J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-370-
hcfmusp.relation.referenceLaMontagne DS, 2011, B WORLD HEALTH ORGAN, V89, P821, DOI [10.2471/BLT.11.089862, 10.2471/BLT.11.08986, 10.1590/S0042-96862011001100012]-
hcfmusp.relation.referenceLehtinen M, 2012, LANCET ONCOL, V13, P89, DOI 10.1016/S1470-2045(11)70286-8-
hcfmusp.relation.referenceLimia A, 2011, EURO SURVEILL, V16-
hcfmusp.relation.referencePaavonen J, 2009, Lancet, V374, P301, DOI 10.1016/S0140-6736(09)61248-4-
hcfmusp.relation.referenceParkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111-
hcfmusp.relation.referenceRondy M, 2010, VACCINE, V28, P2070, DOI 10.1016/j.vaccine.2009.12.042-
hcfmusp.relation.referenceRouzier R, 2010, J ADOLESCENT HEALTH, V47, P237, DOI 10.1016/j.jadohealth.2010.04.006-
hcfmusp.relation.referenceSaslow D, 2007, CA-CANCER J CLIN, V57, P7-
hcfmusp.relation.referenceSimoens C, 2009, EURO SURVEILL, V14-
hcfmusp.relation.referenceSingh Y, 2010, ASIAN PAC J CANCER P, V11, P615-
hcfmusp.relation.referenceStokley S, 2011, PEDIATRICS, V128, P1078, DOI 10.1542/peds.2011-1048-
hcfmusp.relation.referenceVanni T, 2012, VACCINE, V30, P4866, DOI 10.1016/j.vaccine.2012.04.087-
hcfmusp.relation.referenceVilla LL, 2006, BRIT J CANCER, V95, P1459, DOI 10.1038/sj.bjc.6603469-
hcfmusp.relation.referenceVilla LL, 2011, CANCER LETT, V305, P106, DOI 10.1016/j.canlet.2010.12.002-
hcfmusp.relation.referenceVilla LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7-
hcfmusp.relation.referenceWatson M, 2009, AUST NZ J PUBL HEAL, V33, P365, DOI 10.1111/j.1753-6405.2009.00409.x-
hcfmusp.relation.referenceWatson-Jones D, 2012, J INFECT DIS, V206, P678, DOI 10.1093/infdis/jis407-
hcfmusp.relation.referenceWHO, 2012, IMM SUMM STAT REF CO, P198-
hcfmusp.relation.referenceWidgren K, 2011, VACCINE, V29, P9663, DOI 10.1016/j.vaccine.2011.10.021-
hcfmusp.relation.referenceWorld Health Organisation, 2009, WEEKLY EPIDEMIOLOGIC, V15, P118-
hcfmusp.relation.reference[Anonymous], 2011, MMWR MORB MORTAL WKL, V60, P1382-
hcfmusp.relation.reference[Anonymous], 2007, N ENGL J MED, V356, P1915-
hcfmusp.relation.reference[Anonymous], 2010, NAT STAT LOC AR VACC, P1018-
hcfmusp.relation.referenceWHO, 2011, IN VACC RES IVR VIR-
dc.description.indexMEDLINE-
hcfmusp.remissive.sponsorshipCNPq-
hcfmusp.remissive.sponsorshipFAPESP-
hcfmusp.remissive.sponsorshipMerck-
hcfmusp.citation.scopus30-
hcfmusp.scopus.lastupdate2022-05-06-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MPR
Departamento de Medicina Preventiva - FM/MPR

Artigos e Materiais de Revistas Científicas - LIM/14
LIM/14 - Laboratório de Investigação em Patologia Hepática

Artigos e Materiais de Revistas Científicas - LIM/38
LIM/38 - Laboratório de Epidemiologia e Imunobiologia

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_ELUF-NETO_A_School_Based_Human_Papillomavirus_Vaccination_Program_in_2013.PDFpublishedVersion (English)413.78 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.